Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Alfred Binggeli

Hans-Peter Maerki

Johannes Aebi

Peter Mohr

Uwe Grether

Markus Meyer

Hans Peter Maerki

Georges Hirth

Bernd Kuhn

Fabienne Ricklin

Patrizio Mattei

Luke Green

Guido Hartmann

Jean Ackermann

Hans Hilpert

Olivier Roche

Wolfgang Wostl

Matthew Wright

Rainer Eugen Martin

Andreas Dominik Christ

Maurice Wilhelm

Vincent Mutel

Markus Boehringer

Eric Vieira

Marcel Muller

Heinz Stadler

Wolfgang Guba

Holger Kuehne

Daniel Bur

Walter Fischli

Volker Breu

Jean-Michel Adam

Cornelia Hertel

Haiyan Wang

Christian Oefner

Hans-Peter Marki

Anish Ashok Konkar

Luke Gideon Granville Green

Rolf Guller

Beat Wirz

Hans Iding

Geo Adam

Roland Humm

Hans-Peter M&auml;rki

Thierry Masquelin

Andreas D Christ

The invention provides novel compounds having the general formula (I) wherein R, R, R, R, R, R, R, R, R, R, R, Rand A are as described herein, compositions including the compounds and methods of using the compounds.

Biaryl amide derivatives

The invention provides novel compounds having the general formula (I) wherein R, R, R, R, R, R, R, R, R, R, R, R, A, Aand n are as described herein, compositions including the compounds and methods of using the compounds.

Aryl-benzocycloalkyl amide derivatives

The invention is concerned with novel bicyclic compounds of formula (I), wherein A, L, E, F, G, R, R, R, R, R, R, R, V, W and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.

Bicyclic compounds

The invention is concerned with novel bicyclic compounds of formula (I), wherein n, m, p, A, L, R, R, R, R, R, R, R, R, R, R, and Rare as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor may be used, for example, in the prevention and/or treatment of inflammatory diseases, particularly peripheral arterial occlusive diseases or atherothrombosis.

Heterocyclyl compounds

The invention is concerned with novel heteroaryl carboxamide derivatives of formula (I), wherein m, X, Y, R, R, Rand Rare as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor, CCR-5 receptor and/or CCR-3 receptor and can be used as medicaments.

Heteroaryl carboxamide derivatives

The invention is concerned with novel biaryl derivatives of formula (I), wherein m, R, R, R, X, Xand Xare as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor, CCR-5 receptor and/or CCR-3 receptor and can be used as medicaments.

Biaryl derivatives

The invention is concerned with novel heterocyclyl compounds of formula (I): wherein A, X, R, R, R, R, R, R, R, R, m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and may be used as medicaments.

The invention is concerned with novel heterocyclyl compounds of formula (I) wherein A, X, Y, Y, Y, R, R, R, R, R, R, R, R, m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.

The invention is concerned with novel heterocyclyl compounds of formula (I) wherein A, X, Y, R, R, R, R, R, R, R, R, m and n are as herein defined, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.

Heterocyclic compounds

This invention is concerned with compounds of the formula and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

Substituted piperidines as somatostatin receptor subtype 5 (SSTR5) antagonists

The invention is concerned with novel pyrazol derivatives of formula (I), wherein R, R, R, R, X and Y are as defined herein, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor and/or CCR-5 receptor and can be used as medicaments.

Pyrazol derivatives

The invention is concerned with novel imidazole derivatives of formula (I), wherein m, E, R, R, R, R, R, Rand Rare as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor, CCR-5 receptor and/or CCR-3 receptor and can be used as medicaments.

Imidazole derivatives

This invention is concerned with compounds of the formula wherein A, Rto Rand G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

Pyrimidine, quinazoline, pteridine and triazine derivatives

This invention is concerned with compounds of the formula wherein Rto R, Rand A are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

Amide derivatives as somatostatin receptor 5 antagonists

Substituted piperidinamines as somatostatin receptor subtype 5 (SSTR5) antagonists

Growing community of inventors

Binningen, Switzerland

Alfred Binggeli